Answers are grounded in this paper and cite their sources.
Demonstrates improved adherence to CDKIs in breast cancer patients using a mobile health intervention, suggesting effective support tools.
PURPOSE Cyclin-dependent kinase 4 and 6 inhibitors (CDKIs) are effective breast cancer therapies but pose adherence challenges because of cost, side effects, and complexity of medication schedule. We assessed the feasibility and usability of a smart label–enabled remote therapeutic monitoring (RTM) mHealth intervention for women with breast cancer prescribed a CDKI. Exploratory adjusted analyses examined factors associated with usability and CDKI adherence. METHODS Participants were recruited from a comprehensive cancer center between April and August 2024. For 3 months, participants used Tappt smart labels and web app to record CDKI doses, receive missed dose reminders, report symptoms biweekly, and complete baseline and follow-up surveys. Alerts were sent to oncology teams for nonadherence (>20% missed doses) or moderate-to-severe symptoms. Feasibility was defined as ≥70% of participants using the smart label >30 days and completing the follow-up survey. Usability was assessed using the System Usability Scale, with a benchmark score of ≥68. Linear regression was used to examine factors associated with usability and CDKI adherence. RESULTS Among 168 screened, 107 were eligible and reached; 75.7% (81/107) consented; 90.1% (73/81) completed the follow-up survey, and 88.9% (72/81) used the intervention >30 days. Most participants self-identified as White (69.9%), were privately insured (72.6%), and had early-stage breast cancer (58.9%) and depression or anxiety (58.9%). The mean usability score was 75.8; participants who self-identified as Black reported 12.0 points higher usability than those who self-identified as White ( P = .03). Mean CDKI adherence was 92.8%. A history of anxiety or depression was associated with an 8.6 percentage-point lower CDKI adherence rate ( P = .02). CONCLUSION A smart label–enabled RTM mHealth intervention exceeded feasibility and usability benchmarks and showed promise for supporting CDKI adherence and symptom management.
No takes yet. Share an insight, caveat, or question.
Graetz et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: